Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2013)

16 slides from Pharmacyclics's technical presentation, Jun 21, 2013

  1. Slide 1: A Phase II Multicenter Study of the HDAC Inhibitor Abexinostat in FL and MCL

    A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI- 24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) Andrew M. Evens, DO, MSc}, Julie M Vose, MD, MBA2, Wael Harb, MD?, Leo |. Gordon, MD4, Robert Langdon, MD°, Barbara Grant,

  2. Slide 2: HDAC Inhibitors

    HDAC Inhibitors CH, i (CH); “. w — Te = _ Ke “Ae Ae “condensed” “open” + HDAC inhibitor Inhibition of HDAC (histone deacetylase) activity — Induces acetylation of histones and other cellular proteins — Results in the re-expression of silenced genes (e.g., p21) — Leads to tumor cell apoptosis and dow

  3. Slide 3: Abexinostat (PCI-24781/S 78454) — an Oral HDAC Inhibitor

    Abexinostat (PCI-24781/S 78454) — an Oral HDAC Inhibitor HDAC7 — Class Ila * Orally bioavailable with broad spectrum HDAC inhibition * Strong binding affinity (< 20nM Ki) to all Class | and IIb isoforms except for HDAC8 (Ki = 200nM) * Studied in>250 patients with solid tumors and hematologic maligna

  4. Slide 4: PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patients

    PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patients * Phase I: Dose escalation (reported at ASH 2009, Evens et al) — N= 25 (in 4 dose cohorts); revised Cheson staging criteria — Clinical activity noted in follicular lymphoma (FL) and mantle cell lymphoma (MCL) patients: * InFL (n=4)

  5. Slide 5: CR in FL Patient

    CR in FL Patient + Heavily pretreated FL patient (72 year-old Female) + 5 prior treatments: 1) CHOP, 2) FAVID (vaccine), 3) SL11047, 4) doxorubicin, 5) rituximab/doxorubicin/fludarabine + PRat cycle 4, CR at cycle 8 PET/CT’ Baseline 8 cycles PCI-24781

  6. Slide 6: PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patients

    PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patients * Phase Il: in relapsed/refractory FL and MCL patients — N= 30 (16 FL and 14 MCL) — Abexinostat monotherapy given at 45 mg/m? BID 7 d/wk every other week x 2/cycle — Objectives: * Overall response rate * Duration of response, progr

  7. Slide 7: Subject Eligibility in Phase II of PCYC-0403

    Subject Eligibility in Phase Il of PCYC-0403 * Pathologically confirmed FL or MCL * Received one to four prior regimens (prior allogeneic stem cell transplant excluded) « Adequate organ function * ECOG Performance Status < 1 * No CNS lymphoma

  8. Slide 8: Patient Characteristics in Phase II of PCYC-0403

    Patient Characteristics in Phase Il of PC 0403 MCL Total 4) (N=30) ‘Age: Median: 62 67 67 Range: 36-81 59-77 36-81 Gender: Female # (%) 8 (50.0) 2 (14.3) 10 (33.3) Male # (%) 8 (50.0) 12(85.7) 20 (66.7) Prior regimens, # (%) Median 2 3 3 Range 1-4 1-5 1-5 Rituximab 15 (93.8) 14 (100) 29 (96.7) CHOP/

  9. Slide 9: Common AEs in Phase II of PCYC-0403

    Common AEs In Phase II of PCYC-0403 (Events in = 20 % of Patients that were at least possibly related to Abexinostat) Nausea Fatigue Diarrhea Thrombocytopeni Vomiting Anaemia ~ Decreased Appetite - " Grade 1 Neutropenia -/ © Grade 2 8 Grade 3 Pe i 2 z 10% 20% 30% 40% 50% 60% 70% Data cutoff as of Ap

  10. Slide 10: Grade 3 or 4 AEs in Phase II of PCYC-0403

    Grade 3 or 4 AEs in Phase II of PCYC-0403 (Events in > 5 % of Patients that were at least possibly related to Abexinostat) Adverse Event Grade 3 # (%) Grade 4 # (%) Thrombocytopenia 2( 6.7) 3 (10.0) Neutropenia 3 (10.0) 1( 3.3) Fatigue 3 (10.0) 0(0) Anaemia 2( 6.7) 0(0) Arthralgia 2( 6.7) 0(0) * One

  11. Slide 11: Best Response in Phase II of PCYC-0403

    Best Response in Phase II of PCYC-0403 64% co 48% 40% % 369 ; on 36% 36% = PR =CR , sD 27% 28% PD 5 24% 21% 4a: Y 209%) 14% 0% —™ = FL (N=14) NHUMCL (N=11) Total (N=25) *in patients who had baseline and post treatment response assessments Data cutoff as of Apr 3, 2013

  12. Slide 12: Maximum Decrease in Tumor Burden in Phase II of PCYC-0403

    Maximum Decrease In Tumor Burden in Phase II of PCYC-0403* * 12/14(86%) evaluable FL patients had reductionsin sum of product diameters (SPD), 5 of which >75% reduction 100 80 — NHUMCL Ss oO — Follicular % 3 40 & © 9 Mim sy oes > § in 7 | | oar ‘3-20 | g 40 = 2 L 2 60 -80 =e i 128004 oe *in patients

  13. Slide 13: Time on Study with Best Response in Phase II of PCYC-0403

    Time on Study with Best Response in Phase II of PCYC-0403 * 8/9 (89%) of FL responders on study for > 8 months and 5 pts on study/ drug >18 months * Median PFS in FL is 20.5 months (Kaplan-Meier estimate) FL MCL * SPD reduction > 75% Data cutoff as of Apr 3, 2013 all

  14. Slide 14: Conclusions

    Conclusions * Abexinostat (PCI-24781) active in relapsed/ refractory B-cell lymphoma with an ORR of 48% — In FL, 64% ORR noted; responses appear durable — In MCL, ORR of 27% * Safety profile consistent with this class of agents, but with less than 27% of patients experiencing Grade 23 cytopenia (mos

  15. Slide 15: Acknowledgements

    Acknowledgements All the patients and their families who participated in the study. Researchers from all clinical centers. Colleagues from Pharmacyclics.

  16. Slide 16: Backup: PFS for FL patients in Phase II

    Backup: PFS for FL patients in Phase II * Median PFS in FL is 20.5 months (Kaplan-Meier estimate) * Median time on study in FL is 11.9 (1.2-24.8) months Be 08 3 06 é = 04 3 02 + cansred 00 o 2 4 6 8 0 2 14 16 18 2 2 2 Months on Study “The dash ines the median folow-up time of a evaluate FL. patents

Pharmacyclics — Technical Presentation (June 2013) on 6ix